Evidence map›Paper›PMID 37171457›Full record

ArticleAdvanced healthcare materials2023

Organic Electronic Platform for Real-Time Phenotypic Screening of Extracellular-Vesicle-Driven Breast Cancer Metastasis.

Walther C Traberg, Johana Uribe, Victor Druet, Adel Hama, Chrysanthi-Maria Moysidou, Miriam Huerta, Reece McCoy, Daniel Hayward, Achilleas Savva, Amaury M R Genovese and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Organic Electrochemical Transistors for Biomarker Detections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 4 countries.

Walther C TrabergDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB3 0AS, UK.ORCID 0000-0003-2673-2253
Johana UribeRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Olin Hall, Ithaca, NY, 14853, USA.
Victor DruetBiological and Environmental Sciences and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal, 3955, Kingdom of Saudi Arabia.
Adel HamaBiological and Environmental Sciences and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal, 3955, Kingdom of Saudi Arabia.
Chrysanthi-Maria MoysidouDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB3 0AS, UK.
Miriam HuertaRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Olin Hall, Ithaca, NY, 14853, USA.
Reece McCoyDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB3 0AS, UK.
Daniel HaywardEarly Cancer Institute, University of Cambridge, Hutchison Research Centre, Cambridge, CB2 0XZ, UK.
Achilleas SavvaDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB3 0AS, UK.
Amaury M R GenoveseDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB3 0AS, UK.
Suraj PavagadaDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB3 0AS, UK.
Zixuan LuDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB3 0AS, UK.
Anil KokluBiological and Environmental Sciences and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal, 3955, Kingdom of Saudi Arabia.
Anna-Maria PappaDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB3 0AS, UK.
Rebecca FitzgeraldEarly Cancer Institute, University of Cambridge, Hutchison Research Centre, Cambridge, CB2 0XZ, UK.
Sahika InalBiological and Environmental Sciences and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal, 3955, Kingdom of Saudi Arabia.
Susan DanielRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Olin Hall, Ithaca, NY, 14853, USA.
Róisín M OwensDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB3 0AS, UK.ORCID 0000-0001-7856-2108
University of Cambridge · GBKing Abdullah University of Science and Technology · SACornell University · USKhalifa University of Science and Technology · AE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-derived extracellular vesicles (TEVs) induce the epithelial-to-mesenchymal transition (EMT) in nonmalignant cells to promote invasion and cancer metastasis, representing a novel therapeutic target in a field severely lacking in efficacious antimetastasis treatments. However, scalable technologies that allow continuous, multiparametric monitoring for identifying metastasis inhibitors are absent. Here, the development of a functional phenotypic screening platform based on organic electrochemical transistors (OECTs) for real-time, noninvasive monitoring of TEV-induced EMT and screening of antimetastatic drugs is reported. TEVs derived from the triple-negative breast cancer cell line MDA-MB-231 induce EMT in nonmalignant breast epithelial cells (MCF10A) over a nine-day period, recapitulating a model of invasive ductal carcinoma metastasis. Immunoblot analysis and immunofluorescence imaging confirm the EMT status of TEV-treated cells, while dual optical and electrical readouts of cell phenotype are obtained using OECTs. Further, heparin, a competitive inhibitor of cell surface receptors, is identified as an effective blocker of TEV-induced EMT. Together, these results demonstrate the utility of the platform for TEV-targeted drug discovery, allowing for facile modeling of the transient drug response using electrical measurements, and provide proof of concept that inhibitors of TEV function have potential as antimetastatic drug candidates.

Indexed as

Breast NeoplasmsExtracellular VesiclesTriple Negative Breast NeoplasmsCell Line, TumorCell MovementCutaneous Malignant MelanomaEarly Detection of CancerEpithelial-Mesenchymal TransitionFemaleHumansbreast cancer metastasisdrug screeningexosomesextracellular vesiclesorganic electronics

Identifiers

PMID37171457
PMCPMC11468090
OpenAlexW4376224233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.